Fluorescent silica-based nanoparticles

US10548997B2 · kind B2 · utility

Assignees

• Sloan Kettering Institute for Cancer Research · US
• Cornell University · IT

Inventors

• Michelle S. Bradbury · Andover, US
• Ulrich Wiesner · Ithaca, US
• Oula Penate Medina · Kiel, DE
• Hooisweng Ow · Woburn, US
• Andrew Arthur Paul Burns · Niskayuna, US
• Jason S. Lewis · New York, US
• Steven M. Larson · New York, US

Key dates

• Filing date: Mar 1, 2017
• Grant date: Feb 4, 2020
• Expiry date: Mar 1, 2037

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S977/927
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a fluorescent silica-based nanoparticle that allows for precise detection, characterization, monitoring and treatment of a disease such as cancer. The nanoparticle has a range of diameters including between about 0.1 nm and about 100 nm, between about 0.5 nm and about 50 nm, between about 1 nm and about 25 nm, between about 1 nm and about 15 nm, or between about 1 nm and about 8 nm. The nanoparticle has a fluorescent compound positioned within the nanoparticle, and has greater brightness and fluorescent quantum yield than the free fluorescent compound. The nanoparticle also exhibits high biostability and biocompatibility. To facilitate efficient urinary excretion of the nanoparticle, it may be coated with an organic polymer, such as poly(ethylene glycol) (PEG). The small size of the nanoparticle, the silica base and the organic polymer coating minimizes the toxicity of the nanoparticle when administered in vivo. In order to target a specific cell type, the nanoparticle may further be conjugated to a ligand, which is capable of binding to a cellular component associated with the specific cell type, such as a tumor marker. In one embodiment, a therapeut…